CorMedix Inc (CRMD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Anti-infectivesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 21/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 24.35% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged
- CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
- CorMedix (CRMD) Upgraded to Buy: Here's Why
- CorMedix (CRMD) Q2 2026 Earnings Call Transcript
- Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
- Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...
- CorMedix Q2 Earnings Call Highlights
- CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for CorMedix Inc.
Full CRMD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.